drugset

drugset / Trial / NCT01171729

Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

NCT01171729 ↗

Phase 1/2 Completed 12 enrolled Samsung Medical Center National Cancer Center, Korea · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open label, Phase I/IIa trial of immunotherapy with CreaVax-PC as treatment in men with hormone-Refractory Metastatic Prostate Cancer.

Timeline

Start: 2006-07
Primary completion: 2010-05
Completion: 2010-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CreaVax-PC	Cell therapy	—	Other

Indications